Skip to main content

Table 3 Medications taken by 460 Finnish travelers during the trip. The medications are categorized according to indication. The data are presented as numbers and percentages of travelers

From: Travelers’ health problems and behavior: prospective study with post-travel follow-up

 

Number

(%a)

Prophylactic antimalarial use among those recommended (missing data = 6)

289

(98)

 Atovaquone and proguanil

135

(30)

 Mefloquine

70

(15)

 Doxycycline

55

(12)

 Chloroquine

25

(6)

 Other / not known

2

(0)

 Changed drug b

2

(0)

 Failure in use c

7

(2)

Antimicrobials (other than doxicycline) (missing data = 0) d

81

(18)

 Fluoroquinolone

53

(12)

 Macrolide

9

(2)

 Nitroimidazole (metronidazole or tinidatzole)

7

(2)

 Amoxicillin

5

(1)

 Tetracycline

1

(0)

 Other / not known

25

(5)

 Two or more antimicrobials (without doxycycline)

15

(3)

Treatment for malaria (missing data = 0) e

4

(1)

Gastrointestinal medication (missing data = 0)

127

(28)

 Loperamide

115

(25)

 Medicinal charcoal

7

(2)

 Other (laxative, spasmolyte, co-phenotrope)

10

(2)

 Two or more gastrointestinal medications

5

(1)

Analgesic (missing data = 0)

123

(27)

 NSAID

67

(15)

 Paracetamol

59

(13)

 Other / not known

16

(3)

 Two or more analgesics

18

(4)

Antiemetic (missing data = 0)

4

(1)

PPI or antacid (missing data = 4)

36

(8)

 PPI

26

(6)

 Antacid (salts/H2)

10

(2)

Probiotics and prebiotics (missing data = 3) f

270

(59)

 Starting before travel

11

(2)

 Using only during travel

123

(27)

 Starting before and using during travel

136

(30)

  1. a Total use of all travelers among those from whom information was available
  2. b Each of these changed the medication from doxycycline to mefloquine
  3. c Did not use as recommended (2 did not take at all, 1 stopped because of adverse effects, 4 used irregularly): atovaquone/proguanil (4), doxycycline (2), mefloquine (1); 10 had prescription but did not enter malaria area; 33 traveled to endemic countries yet visited only low prevalence areas
  4. d 52 (11 % of all) used antimicrobials for TD
  5. e All in Africa, three of four were tested; two negative, one positive
  6. f If only product mentioned, presumed to be used while traveling